Industries > Pharma > Global Asthma & COPD Therapies Market 2019-2029

Global Asthma & COPD Therapies Market 2019-2029

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

PUBLISHED: 19 March 2019
PAGES: 309
PRODUCT CODE: PHA0359
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 309-page report you will receive 112 tables and 131 figures– all unavailable elsewhere.

The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
• Bronchodilators monotherapy
• Anti-inflammatory drugs
• Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
• Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
• Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
• Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
• Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
• Anti-leukotrienes: Singulair
• Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
• Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:
• The US
• Japan
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Mexico
• Other Countries

Global Asthma & COPD Therapies Market 2019-2029

• This report discusses the leading companies in the global asthma & COPD therapies market:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Asthma & COPD Therapies Market Analysis : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029

    Download sample pages

    Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ